Saat rata-rata pengikut agama Islam yagn ajarannnya dungu, buas, kejam, kej,
ganas, zalim lagi biadab itu sibuk membuang-buang waktunya untuk zikir dan
tungang tunggik kayak onta dientotin jirapah lima kali sehari menyembah Allah
fiktif; saat ratusan ribu diantar mereka sibuk tiap tahun membuang-buang duit
unutk naik haji sembari lari-lari kayak orang sedeng di Makkah sono dan
melempari setan yang nggak ada di padang pasir sono; saat mereka itu sibuk
saling berbunuhan dan bikin onar....
Orang kafir tidak henti-hentinya melakukan penelitian untuk memajukan ilmu
ketabiban dan berbagai cabang ilmu pengetahuan lain......
----
BBC NEWS
Cancer drug success 'on the rise'
Cancer drug research is entering a new era which will mean more successful
drugs for patients, says a charity.
However, Cancer Research UK called for pharmaceutical firms and academics to be
more open about those which do not make the grade.
Improved knowledge of cancer's biology means 18% of new drugs, compared to 5%
previously - will become standard treatments, said the charity's experts.
Their research was published in the journal Nature Reviews Drug Discovery.
We strongly believe that both industry and academia must improve the
availability of data related to failed as well as successful drug development
programmes
Professor Herbie Newell
Cancer Research UK
The hunt for cancer drugs is carried out on a massive scale, but there is also
a massive failure rate, as promising candidates fall by the wayside in clinical
trials.
This costs drug firms and charities such as Cancer Research UK many millions,
although scientists can learn lessons even from expensive failures.
Some studies have estimated that, in the past, just 5% of cancer drugs in the
pipeline actually end up in the clinic being used day to day.
Data on 974 drugs under development, gathered by Cancer Research UK experts,
suggests that 18% of them will prove successful in clinical trials.
It is hoped that many of them will be alternatives to conventional
chemotherapy, which can have unpleasant and dangerous side-effects, targeting
the mechanisms of cancer cells more directly, with less damage to healthy cells.
Genetic make-up
Dr Ian Walker, the licensing manager at the charity's commercial development
arm, said: "This clearly demonstrates the benefits of developing molecularly
targeted treatments for cancer - understanding more about the basic biology of
cancer is making a real difference to the success rate for new anti-cancer drug
development."
The ability to tailor drug choices to the genetic make-up of patients in some
cases is also having a benefit.
However, Professor Herbie Newell, also from Cancer Research UK, said that
minimising the number of "failures" - and their cost to the industry - would be
vital, and this could be helped if researchers and drug companies were more
open about what worked, and what did not:
"We strongly believe that both industry and academia must improve the
availability of data related to failed as well as successful drug development
programmes.
"The sharing of such information can only be beneficial for clinical,
scientific and commercial reasons - and will help measure our progress as well
as pinpoint areas for improvement."
Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/7728821.stm
Published: 2008/11/16 00:00:22 GMT
© BBC MMVIII
---------------
Jusfiq Hadjar gelar Sutan Maradjo Lelo
Allah yang disembah orang Islam tipikal dan yang digambarkan oleh al-Mushaf itu
dungu, buas, kejam, keji, ganas, zalim lagi biadab hanyalah Allah fiktif.
